These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

110 related items for PubMed ID: 712603

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Effect of formulation and process variables on bioequivalency of nitrofurantoin I: preliminary studies.
    Mendes RW, Masih SZ, Kanumuri RR.
    J Pharm Sci; 1978 Nov; 67(11):1613-6. PubMed ID: 712602
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Clinical bioavaiability of nitrofurantoin--a case of bioinequivalence.
    DiSanto AR, Chodos DJ, Phillips JP, DeSante KA, Stoll RG.
    Int J Clin Pharmacol Biopharm; 1976 Apr; 13(3):220-7. PubMed ID: 950266
    [Abstract] [Full Text] [Related]

  • 5. Pharmaceutical availability from oral dosage forms: in vitro release of nitrofurantoin from tablets and capsules.
    Senjković R, Kallay N, Vilendecić M.
    Pharmazie; 1987 Mar; 42(3):186-8. PubMed ID: 3602077
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Studies on freeze-dried drug-milk formulations. II: Effect of regenerated fluid volume on nitrofurantoin bioavailability.
    Macheras PE, Reppas CI.
    J Pharm Sci; 1986 Dec; 75(12):1145-50. PubMed ID: 3559923
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Evaluation of in vitro release rate and in vivo absorption characteristics of four metoprolol tartrate immediate-release tablet formulations.
    Rekhi GS, Eddington ND, Fossler MJ, Schwartz P, Lesko LJ, Augsburger LL.
    Pharm Dev Technol; 1997 Feb; 2(1):11-24. PubMed ID: 9552427
    [Abstract] [Full Text] [Related]

  • 11. In vivo/in vitro correlations of nitrofurantoin matrix tablet formulations.
    Karasulu HY, Ertan G, Köse T, Günerí T.
    Eur J Drug Metab Pharmacokinet; 1996 Feb; 21(1):27-31. PubMed ID: 8839675
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Sustained-release dosage form of nitrofurantoin. Part 2. In vivo urinary excretion in man.
    Ertan G, Karasulu E, Abou-Nada M, Tosun M, Ozer A.
    J Microencapsul; 1994 Feb; 11(2):137-40. PubMed ID: 8006760
    [Abstract] [Full Text] [Related]

  • 17. In vitro release and in vivo absorption of nitrofurantoin and nalidixic acid from ethylcellulose microcapsules.
    Hashim F, Sakr FM, el Din EZ.
    Pharmazie; 1987 May; 42(5):315-7. PubMed ID: 3671441
    [Abstract] [Full Text] [Related]

  • 18. Preparation of microcapsules from complex coacervation of Gantrez-gelatin. II. In vitro dissolution of nitrofurantoin microcapsules.
    Mortada SA, el Egaky AM, Motawi AM, el Khodery KA.
    J Microencapsul; 1987 May; 4(1):23-37. PubMed ID: 3504494
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Identification of formulation and manufacturing variables that influence in vitro dissolution and in vivo bioavailability of propranolol hydrochloride tablets.
    Eddington ND, Ashraf M, Augsburger LL, Leslie JL, Fossler MJ, Lesko LJ, Shah VP, Rekhi GS.
    Pharm Dev Technol; 1998 Nov; 3(4):535-47. PubMed ID: 9834957
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.